Benzinga | Oct 8, 2021 06:28AM EDT

Goldman Sachs Downgrades Allogene Therapeutics to Neutral, Lowers Price Target to $20

Goldman Sachs analyst Salveen Richter downgrades Allogene Therapeutics (NASDAQ:ALLO) from Buy to Neutral and lowers the price target from $71 to $20.